SPECIALTY GUIDELINE MANAGEMENT

RECLAST (zoledronic acid)
zoledronic acid

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications
   1. Treatment and prevention of osteoporosis in postmenopausal women
   2. Treatment to increase bone mass in men with osteoporosis
   3. Treatment and prevention of glucocorticoid-induced osteoporosis
   4. Treatment of Paget’s disease of bone in men and women

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

A. Postmenopausal osteoporosis, treatment and prevention
   Authorization of 12 months may be granted to postmenopausal members for treatment or prevention of osteoporosis when ANY of the following criteria are met:
   1. Member has a history of fragility fractures
   2. Member has a pre-treatment T-score less than or equal to -2.5
   3. Member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1)

B. Osteoporosis in men
   Authorization of 12 months may be granted to male members with osteoporosis when ANY of the following criteria are met:
   1. Member has a history of an osteoporotic vertebral or hip fracture
   2. Member has a pre-treatment T-score less than or equal to -2.5
   3. Member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B)

C. Glucocorticoid-induced osteoporosis
   Authorization of 12 months may be granted for members with glucocorticoid-induced osteoporosis when BOTH of the following criteria are met:
   1. Member is currently receiving or will be initiating glucocorticoid therapy
   2. Member meets ANY of the following criteria:
a. Member has a history of a fragility fracture
b. Member has a pre-treatment T-score of less than or equal to -2.5
c. Member has osteopenia (i.e., pre-treatment T-score greater than -2.5 and less than -1) with a high pre-treatment FRAX fracture probability (See Appendix B)

D. Paget’s disease of bone
Authorization of one dose (5 mg) may be granted for treatment of Paget’s disease of bone.

III. CONTINUATION OF THERAPY

A. Paget’s disease of bone
All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

B. All other indications
Authorization of 12 months may be granted for all members (including new members) who meet all initial authorization criteria and experiences clinical benefit after at least 12 months of therapy with zoledronic acid or Reclast as evidenced by improvement or stabilization in T-score.

IV. APPENDIX

Appendix A. Clinical reasons to avoid oral bisphosphonate therapy
- Esophageal abnormality that delays emptying such as stricture of achalasia
- Active upper gastrointestinal problem (e.g., dysphagia, gastritis, duodenitis, erosive esophagitis, ulcers)
- Inability to stand or sit upright for at least 30 to 60 minutes
- Inability to take at least 30 to 60 minutes before first food, drink, or medication of the day
- Renal insufficiency (creatinine clearance <35 mL/min)
- History of intolerance to an oral bisphosphonate

Appendix B. WHO Fracture Risk Assessment Tool
- High FRAX fracture probability: 10 year major osteoporotic fracture risk ≥ 20% or hip fracture risk ≥ 3%
- 10-year probability; calculation tool available at: https://www.sheffield.ac.uk/FRAX/
- The estimated risk score generated with FRAX should be multiplied by 1.15 for major osteoporotic fracture and 1.2 for hip fracture if glucocorticoid treatment is greater than 7.5 mg (prednisone equivalent) per day.

V. REFERENCES


